Priapism
Methodology & AI Transparency ⓘ
Priapism Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Priapism is an ICD-10-CM indexed diagnosis (N48.30) within Prostate (BPH), Bladder & Urinary Tract.
- 2 Real-world patient consensus: Federal ICD-10-CM code N48.30 categorizes Priapism under Prostate (BPH), Bladder & Urinary Tract.
- 3 Typical cash cost range: Clinicians assessing Priapism focus on prostatic fibromuscular stromal in Priapism (N48.30: hyperplasia) and targeted history.
- 4 Top reported side effects / signs: Key Urology & Prostate biomarkers for Priapism (N48.30): IPSS Urinary Symptom in Priapism (N48.30: Score) & Urinalysis & Post-Void in Priapism (N48.30: Residual (PVR)) (Negative leukocyte/nitrite; PVR < 50 mL (N48.30)).
Ask our AI Specialists anything about Priapism
What Is Priapism?
Priapism is an ICD-10-CM indexed diagnosis (N48.30) within Prostate (BPH), Bladder & Urinary Tract. Clinical evaluation centers on urinalysis/urine culture [Priapism N48.30] alongside serial IPSS Urinary Symptom in Priapism (N48.30: Score) tracking (0 – 7 (mild symptoms) (N48.30)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Priapism (N48.30) alters urology & prostate homeostasis through prostatic fibromuscular stromal in Priapism (N48.30: hyperplasia); clinical remission targets Urinalysis & Post-Void in Priapism (N48.30: Residual (PVR)) within Negative leukocyte/nitrite; PVR < 50 mL (N48.30).
Common Symptoms & Clinical Signs
- • Presentation of Priapism (N48.30): weak, hesitant, or in Priapism (N48.30: intermittent urinary stream)
- • Secondary Priapism clinical sign: waking two or in Priapism (N48.30: more times nightly)
- • Symptom flares in Priapism correlating with IPSS Urinary Symptom in Priapism (N48.30: Score) deviation outside 0 – 7 (mild symptoms) (N48.30)
- • Functional urology & prostate impact requiring urinalysis/urine culture [Priapism N48.30] evaluation (N48.30)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Priapism Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N48.30 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Priapism (N48.30: Score) | 0 – 7 (mild symptoms) (N48.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Priapism (N48.30: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N48.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Priapism (N48.30: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N48.30) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Priapism
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Betaxolol Hydrochloride Betoptic S, Betoptic • RxCUI 308720 | beta-Adrenergic Blocker | 79% | $38.7842 | $ 32.32 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Priapism)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Rilzabrutinib was well-tolerated, with similar side effects reported in both groups. The Journal of investigative dermatology • 2024-08-15 • Phase III Randomized Trial | N = 65 | 88/100 | PMID 38493933 ↗ |
| New Insights on Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical: What a 824-Participant Study Found A clinically integrated trial using cluster randomization accrued rapidly with no important logistical problems and negligible burden on surgeons. The Journal of urology • 2021-09-15 • Phase III Randomized Trial | N = 824 | 87/100 | PMID 33904798 ↗ |
| Can This Approach Help? Inside the Latest Research on Multicenter noninferiority phase III clinical trial of the first biosimilar of The data obtained confirm that the Biosimilar is not inferior to the Originator in terms of the main efficacy parameter, and is also comparable with it in terms of safety and additional efficacy parameters. Annals of hematology • 2021-11-15 • Phase III Randomized Trial | N = 16 | 82/100 | PMID 34398258 ↗ |
Priapism Patient Community & “People Like Me” Threads
Filter Priapism community threads and patient logs by age, biological sex, dosage, and treatment duration.